Sherbrooke Park Advisers LLC Monte Rosa Therapeutics, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 14,476 shares of GLUE stock, worth $98,147. This represents 0.03% of its overall portfolio holdings.
Number of Shares
14,476
Previous 19,993
27.59%
Holding current value
$98,147
Previous $106 Million
5.19%
% of portfolio
0.03%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding GLUE
# of Institutions
102Shares Held
49.1MCall Options Held
285KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$52.2 Million3.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.12MShares$48.3 Million0.01% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$38.3 Million58.01% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$33.3 Million0.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.35MShares$29.5 Million0.44% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $317M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...